Program
SKB571
A development code. Also written as “SKB571 for injection”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Digestive System Neoplasms · Pancreatic Neoplasms · Squamous Cell Carcinoma of Head and Neck · Lung Neoplasms, led by Sichuan Kelun Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sichuan Kelun Pharmaceutical | 77 open or running | phase 2since Nov 13, 2025 | Nov 28, 2024 | Dec 2026phase 1 · NCT06725381 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 28, 2024First study: phase 1 study in Solid MalignanciesFirst studyNCT06725381 · 138 planned · China
- Nov 13, 2025Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07230405 · 295 planned · China
- Dec 15, 2025Phase 2 study in Non-small Lung CancerNCT07308106 · 70 planned · China
- Apr 14, 2026Phase 2 study in Digestive System NeoplasmsNCT07564466 · 160 planned · China
- May 26, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07622186 · 150 planned · China
- Jun 16, 2026Phase 2 study in Squamous Cell Carcinoma of Head and NeckNCT07668154 · 120 planned · China
- Sep 2, 2026Phase 2 study in Pancreatic NeoplasmsNCT07814066 · 30 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Solid MalignanciesNCT06725381
- Jun 30, 2027Primary completion: phase 2 study in Non-small Lung CancerNCT07308106
- Aug 31, 2027Primary completion: phase 2 study in Digestive System NeoplasmsNCT07564466
- Jan 19, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07230405
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07814066Pancreatic Neoplasms | 2 | Not yet recruiting | Feb 28, 2028 | 30 |
| NCT07668154Squamous Cell Carcinoma of Head and Neck · China | 2 | Recruiting | Sep 30, 2028 | 120 |
| NCT07622186Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Dec 31, 2028 | 150 |
| NCT07564466Digestive System Neoplasms · China | 2 | Recruiting | Aug 31, 2027 | 160 |
| NCT07308106Non-small Lung Cancer · China | 2 | Recruiting | Jun 30, 2027 | 70 |
| NCT07230405Carcinoma, Non-Small-Cell Lung · China | 2 | Recruiting | Jan 19, 2028 | 295 |
| NCT06725381Solid Malignancies · China | 1 | Recruiting | Dec 2026 | 138 |
How it is read
Names in the registry
- “SKB571 for injection”, 4 entries
- “SKB571”, 3 entries
Codes read as this program: SKB571.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Digestive System Neoplasms, 1 study
- Pancreatic Neoplasms, 1 study
- Squamous Cell Carcinoma of Head and Neck, 1 study
- Lung Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.